Patent Issued for Neutrophil suppression as preconditioning to increase oncolytic bacterial therapy (USPTO 12109177).

A patent issued by Johns Hopkins University discusses a method to increase the therapeutic efficiency of oncolytic bacterial therapy for solid tumors. The patent focuses on using immunoregulatory compounds, such as hydroxyurea, to suppress neutrophils before administering anaerobic bacteria to treat tumors. This approach aims to enhance tumor clearance and reduce treatment-related toxicities, addressing the challenges faced in current cancer therapies. The patent provides detailed methods and compounds for treating various types of solid tumors, emphasizing the importance of neutrophil suppression in improving the efficacy of oncolytic bacterial therapy. [Extracted from the article]